EU/3/14/1249: Orphan designation for the treatment of familial chylomicronaemia syndrome

Phosphorothioate oligonucleotide targeted to apolipoprotein C-III (volanesorsen)

Overview

On 19 February 2014, orphan designation (EU/3/14/1249) was granted by the European Commission to Isis USA Ltd, United Kingdom, for phosphorothioate oligonucleotide targeted to apolipoprotein C-III for treatment of familial chylomicronaemia syndrome.

In April 2016, Isis USA Ltd changed name to Ionis USA Ltd.

The sponsorship was transferred to Akcea Therapeutics UK Ltd., United Kingdom, in July 2017 and subsequently to Akcea Therapeutics Ireland Limited, Ireland, in March 2019.

 

Key facts

Active substance
Phosphorothioate oligonucleotide targeted to apolipoprotein C-III (volanesorsen)
Intented use
Treatment of familial chylomicronaemia syndrome
Orphan designation status
Positive
EU designation number
EU/3/14/1249
Date of designation
19/02/2014
Sponsor

Akcea Therapeutics Ireland Limited
Regus House
Harcourt Centre
Harcourt Road
Dublin 2
Ireland
Tel: + 353 1 477 3197
E-mail: JMacPherson@akceatx.com

 

Review of designation

This medicine is now known as volanesorsen.

Phosphorothioate oligonucleotide targeted to apolipoprotein C-III for treatment of familial chylomicronemia syndrome has been authorised in the EU as Waylivra since 3 May 2019.

The Committee for Orphan Medicinal Products reviewed the orphan designation of Waylivra at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the PDF icon orphan medicine assessment report

For recommended INNs since designation please refer to the instructions in the PIS table above. 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating